Status:
ACTIVE_NOT_RECRUITING
Resistance Training Intervention to Improve Physical Function in Patients With Pancreatic Cancer Receiving Combination Chemotherapy or Have Undergone Surgery, PancStrength Study
Lead Sponsor:
M.D. Anderson Cancer Center
Conditions:
Advanced Pancreatic Adenocarcinoma
Pancreatic Adenocarcinoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This clinical trial studies the safety of a real-time tele-exercise resistance training (training done using a tablet) in maintaining skeletal muscle, strength, physical function, and health-related q...
Detailed Description
PRIMARY OBJECTIVE: I. Evaluate the safety of a progressive, home-based, tele-exercise resistance training (tele-RT) intervention in patients undergoing first line FOLFIRINOX chemotherapy for advanced...
Eligibility Criteria
Inclusion
- Biopsy-proven pancreatic adenocarcinoma, advanced stage (III-IV) (study 1) OR biopsy-proven pancreatic adenocarcinoma, at least 10 weeks post-surgical tumor resection and currently with no radiographic evidence of disease on recent computerized tomography (CT) scan (study 2)
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Treatment plan of first-line FOLFIRINOX chemotherapy with planned return visit to MD Anderson Main Campus for restaging (study 1) OR plans to return to MDACC for restaging appointments in 3-4 months, including follow up CT scan (study 2)
- Able to schedule baseline (T0) appointment for fitness testing and program teaching at the Behavioral Research and Treatment Center (BRTC) or able to schedule remote fitness testing and program teaching
- Able to understand the description of the study, exercise program, and willing to participate
- Home access to wireless internet (Wi-Fi) and agreement to engage with study personnel for real-time tele-RT sessions
- Age \>= 18
- Meet all screening requirements
- PROVIDERS (FOR ACCEPTABILITY INTERVENTION): All GI medical oncologists, GI surgeons, advanced practice providers, and clinical dietitians who are involved in participants' care and have some interaction with intervention personnel during recruitment, referral, scheduling, or follow up will be asked to complete questionnaires assessing intervention acceptability. The exact number of providers who will be asked to complete questionnaires will depend on whether patients enroll from the different GI Medical Oncology and GI Surgery clinics, but we expect 10-20 providers to be eligible
Exclusion
- Non-English speaking
- Has participated in regular RT (RT for all major muscle groups at least twice per week) throughout the month prior to recruitment
- Unable to complete the baseline assessment questionnaires or functional assessments
- Screen failure for exercise safety based on Physical Activity Readiness Questionnaire (PAR-Q) and/or Patient Reported Outcomes Measurement Information System (PROMIS) questions
- Underlying unstable cardiac or pulmonary disease or symptomatic cardiac disease (New York Heart Association functional class III or IV)
- Recent fracture or acute musculoskeletal injury that precludes the ability to weight bear fully on all 4 limbs in order to participate in an exercise intervention
- Numeric pain rating scale of \>= 7 out of 10
- Myopathic or rheumatologic disease that impacts physical function
- FEMALES ONLY: Known pregnancy, as communicated to study personnel by clinicians in gastrointestinal (GI) Medical Oncology; females of childbearing potential receive advice to use methods of contraception per usual care
Key Trial Info
Start Date :
February 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2026
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT04837118
Start Date
February 15 2021
End Date
December 31 2026
Last Update
October 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030